Novartis's $90 million Swiss factory to help solve cell therapy bottleneck

Topics Novartis

Swiss drugmaker Novartis's new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020.

The new gene and cell therapy factory, expected to employ 450 people, will allow the drugmaker to make its Kymriah treatment for European patients without first having to fly their immune cells across the Atlantic Ocean. The Swiss factory, as well as a separate French site also being expanded, are.....

This article is no longer available in our repository.

There could be multiple reasons for this.